PL1879624T3 - Terapia genowa dla zaburzeń neurometabolicznych - Google Patents

Terapia genowa dla zaburzeń neurometabolicznych

Info

Publication number: PL1879624T3
Authority: PL; Poland
Prior art keywords: disorders; disease; nervous system; central nervous; gene therapy
Prior art date: 2005-05-02

Application number

PL06759081T

Other languages

English (en)

Inventor

Marco A Passini

James Dodge

Gregory R Stewart

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-02

Filing date

2006-05-02

Publication date

2012-02-29

2006-05-02 Application filed by Genzyme Corp filed Critical Genzyme Corp

2012-02-29 Publication of PL1879624T3 publication Critical patent/PL1879624T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14041—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)

PL06759081T 2005-05-02 2006-05-02 Terapia genowa dla zaburzeń neurometabolicznych PL1879624T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US67705705P	2005-05-02	2005-05-02
US68580805P	2005-05-31	2005-05-31
PCT/US2006/017242 WO2006119458A1 (en)	2005-05-02	2006-05-02	Gene therapy for neurometabolic disorders
EP06759081A EP1879624B1 (en)	2005-05-02	2006-05-02	Gene therapy for neurometabolic disorders

Publications (1)

Publication Number	Publication Date
PL1879624T3 true PL1879624T3 (pl)	2012-02-29

Family

ID=37308324

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL06759081T PL1879624T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych
PL16162716T PL3058959T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych
PL19153520T PL3520823T3 (pl)	2005-05-02	2006-05-02	Terapia genowa zaburzeń neurometabolicznych
PL11169633.2T PL2420256T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
PL16162716T PL3058959T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych
PL19153520T PL3520823T3 (pl)	2005-05-02	2006-05-02	Terapia genowa zaburzeń neurometabolicznych
PL11169633.2T PL2420256T3 (pl)	2005-05-02	2006-05-02	Terapia genowa dla zaburzeń neurometabolicznych

Country Status (13)

Country	Link
US (2)	US10632213B2 (pl)
EP (4)	EP1879624B1 (pl)
JP (3)	JP5829372B2 (pl)
CN (4)	CN107007842A (pl)
AT (1)	ATE525092T1 (pl)
AU (1)	AU2006243776A1 (pl)
BR (1)	BRPI0611379A2 (pl)
CA (2)	CA2998603C (pl)
ES (1)	ES2887076T3 (pl)
IL (2)	IL187078A (pl)
PL (4)	PL1879624T3 (pl)
PT (4)	PT3058959T (pl)
WO (1)	WO2006119458A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2394482T3 (es) *	2005-05-02	2013-02-01	Genzyme Corporation	Terapia génica para trastornos de la médula espinal
PL1879624T3 (pl)	2005-05-02	2012-02-29	Genzyme Corp	Terapia genowa dla zaburzeń neurometabolicznych
EP3540054A3 (en)	2006-06-07	2019-10-09	Genzyme Corporation	Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
WO2008154198A1 (en) *	2007-06-06	2008-12-18	Genzyme Corporation	Gene therapy for lysosomal storage diseases
US8735082B2 (en)	2008-11-10	2014-05-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Gene signature for predicting prognosis of patients with solid tumors
EP3988660A1 (en)	2009-05-02	2022-04-27	Genzyme Corporation	Gene therapy for neurodegenerative disorders
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
US20130090374A1 (en) *	2011-04-20	2013-04-11	Miguel Sena-Esteves	Methods for the treatment of tay-sachs disease, sandhoff disease, and gm1-gangliosidosis
WO2015191508A1 (en)	2014-06-09	2015-12-17	Voyager Therapeutics, Inc.	Chimeric capsids
AU2015343037B2 (en)	2014-11-05	2019-01-17	Voyager Therapeutics, Inc.	AADC polynucleotides for the treatment of parkinson's disease
AU2015346164B2 (en)	2014-11-14	2020-01-30	Voyager Therapeutics, Inc.	Modulatory polynucleotides
MX2017006216A (es)	2014-11-14	2018-08-29	Voyager Therapeutics Inc	Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
US11319555B2 (en)	2014-11-20	2022-05-03	Duke University	Compositions, systems and methods for cell therapy
EP3230441A4 (en)	2014-12-12	2018-10-03	Voyager Therapeutics, Inc.	Compositions and methods for the production of scaav
SG11201706445SA (en) *	2015-02-10	2017-09-28	Genzyme Corp	Enhanced delivery of viral particles to the striatum and cortex
EP3273982B1 (en) *	2015-03-26	2020-11-18	Suzhou Auzone Biological Technology Co., Ltd	Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
WO2016196507A1 (en) *	2015-05-29	2016-12-08	University Of Iowa Research Foundation	Methods of delivery of transgenes for treating brain diseases
EP3448987A4 (en)	2016-04-29	2020-05-27	Voyager Therapeutics, Inc.	COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP3448874A4 (en)	2016-04-29	2020-04-22	Voyager Therapeutics, Inc.	COMPOSITIONS FOR TREATING A DISEASE
CN109831916B (zh)	2016-05-18	2023-07-21	沃雅戈治疗公司	治疗亨廷顿氏舞蹈病的组合物和方法
IL302748A (en)	2016-05-18	2023-07-01	Voyager Therapeutics Inc	modulatory polynucleotides
EP3506817A4 (en)	2016-08-30	2020-07-22	The Regents of The University of California	METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM
JOP20190200A1 (ar)	2017-02-28	2019-08-27	Univ Pennsylvania	تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3061368A1 (en)	2017-05-05	2018-11-08	Voyager Therapeutics, Inc.	Compositions and methods of treating huntington's disease
EP3618839A4 (en)	2017-05-05	2021-06-09	Voyager Therapeutics, Inc.	COMPOSITIONS AND TREATMENT METHODS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS)
NZ760232A (en)	2017-06-07	2023-05-26	Regeneron Pharma	Compositions and methods for internalizing enzymes
JOP20190269A1 (ar)	2017-06-15	2019-11-20	Voyager Therapeutics Inc	بولي نوكليوتيدات aadc لعلاج مرض باركنسون
EP3654860A1 (en)	2017-07-17	2020-05-27	Voyager Therapeutics, Inc.	Trajectory array guide system
CN111448308A (zh)	2017-08-03	2020-07-24	沃雅戈治疗公司	递送aav的组合物和方法
WO2019079242A1 (en)	2017-10-16	2019-04-25	Voyager Therapeutics, Inc.	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP4124658A3 (en)	2017-10-16	2023-04-19	Voyager Therapeutics, Inc.	Treatment of amyotrophic lateral sclerosis (als)
KR20240126916A (ko) *	2023-02-14	2024-08-22	경북대학교 산학협력단	Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8303626D0 (sv)	1983-06-23	1983-06-23	Kabigen Ab	A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5672344A (en)	1987-12-30	1997-09-30	The Regents Of The University Of Michigan	Viral-mediated gene transfer system
US5773278A (en)	1991-05-03	1998-06-30	Mount Sinai Medical Center	Acid sphingomyelinase gene
WO1995000655A1 (en)	1993-06-24	1995-01-05	Mc Master University	Adenovirus vectors for gene therapy
ATE437232T1 (de)	1993-10-25	2009-08-15	Canji Inc	Rekombinanter adenoviren-vektor und verfahren zur verwendung
CA2176117C (en)	1993-11-09	2006-01-03	Terence R. Flotte	Generation of high titers of recombinant aav vectors
US7252989B1 (en)	1994-04-04	2007-08-07	Board Of Regents, The University Of Texas System	Adenovirus supervector system
DE69535703T2 (de)	1994-04-13	2009-02-19	The Rockefeller University	AAV-vermittelte Zufuhr von DNA an Zellen des Nervensystems
AU1525797A (en)	1996-04-22	1997-11-12	Medtronic, Inc.	Two-stage angled venous cannula
US6544785B1 (en)	1998-09-14	2003-04-08	Mount Sinai School Of Medicine Of New York University	Helper-free rescue of recombinant negative strand RNA viruses
WO2001036603A2 (en) *	1999-11-17	2001-05-25	Avigen, Inc.	Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US20030165481A1 (en) *	2000-02-24	2003-09-04	Hersh Louis B.	Amyloid peptide inactivating enzyme to treat Alzheimer's disease
ES2252293T3 (es)	2000-09-18	2006-05-16	Genzyme Corporation	Vectores de expresion que contienene promotores hibridos de ubiquitina.
US20030050273A1 (en) *	2001-08-29	2003-03-13	Keiya Ozawa	Compositions and methods for treating neurodegenerative diseases
US7232670B2 (en) *	2001-09-28	2007-06-19	St. Jude Children's Research Hospital	Targeting proteins to cells expressing mannose receptors via expression in insect cells
ES2975413T3 (es)	2001-12-17	2024-07-05	Univ Pennsylvania	Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas
US6998118B2 (en)	2001-12-21	2006-02-14	The Salk Institute For Biological Studies	Targeted retrograde gene delivery for neuronal protection
EP1478236B1 (en)	2001-12-21	2009-02-11	The Salk Institute For Biological Studies	Targeted retrograde gene delivery to motor neurons
AU2003220115A1 (en) *	2002-05-20	2003-12-12	Board Of Regents, The University Of Texas System	Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
US20040258666A1 (en) *	2003-05-01	2004-12-23	Passini Marco A.	Gene therapy for neurometabolic disorders
EP3513814A1 (en) *	2003-05-01	2019-07-24	Genzyme Corporation	Gene therapy for neurometabolic disorders
US7740168B2 (en)	2003-08-18	2010-06-22	Visa U.S.A. Inc.	Method and system for generating a dynamic verification value
WO2005035743A1 (fr) *	2003-10-15	2005-04-21	Vector Gene Technology Company Ltd.	Procede de production, d'isolation, de purification et utilisations de vecteurs virus adeno-associes recombinants multi-types
EP1716870A1 (en)	2005-04-29	2006-11-02	Bracco Imaging S.p.A.	MRI contrast agents endowed with concentration independent responsiveness
PL1879624T3 (pl)	2005-05-02	2012-02-29	Genzyme Corp	Terapia genowa dla zaburzeń neurometabolicznych
ES2394482T3 (es)	2005-05-02	2013-02-01	Genzyme Corporation	Terapia génica para trastornos de la médula espinal
PL1986661T3 (pl)	2006-02-08	2019-02-28	Genzyme Corporation	Terapia genowa choroby Niemanna-Picka typu A
JP2014513727A (ja)	2011-05-16	2014-06-05	ジェンザイム・コーポレーション	Ｃｘｃｒ４拮抗薬の使用
TWI821227B (zh)	2017-12-22	2023-11-11	美商健臻公司	胺甲喋呤誘發的免疫耐受性之生物標記

2006
- 2006-05-02 PL PL06759081T patent/PL1879624T3/pl unknown
- 2006-05-02 PT PT16162716T patent/PT3058959T/pt unknown
- 2006-05-02 JP JP2008510224A patent/JP5829372B2/ja active Active
- 2006-05-02 PL PL16162716T patent/PL3058959T3/pl unknown
- 2006-05-02 CA CA2998603A patent/CA2998603C/en active Active
- 2006-05-02 PT PT06759081T patent/PT1879624E/pt unknown
- 2006-05-02 WO PCT/US2006/017242 patent/WO2006119458A1/en active Application Filing
- 2006-05-02 EP EP06759081A patent/EP1879624B1/en active Active
- 2006-05-02 PL PL19153520T patent/PL3520823T3/pl unknown
- 2006-05-02 CN CN201611031204.7A patent/CN107007842A/zh active Pending
- 2006-05-02 AU AU2006243776A patent/AU2006243776A1/en not_active Abandoned
- 2006-05-02 CA CA2607173A patent/CA2607173C/en active Active
- 2006-05-02 PT PT19153520T patent/PT3520823T/pt unknown
- 2006-05-02 ES ES19153520T patent/ES2887076T3/es active Active
- 2006-05-02 EP EP11169633.2A patent/EP2420256B1/en active Active
- 2006-05-02 PL PL11169633.2T patent/PL2420256T3/pl unknown
- 2006-05-02 PT PT111696332T patent/PT2420256T/pt unknown
- 2006-05-02 CN CN201710506914.9A patent/CN107362371A/zh active Pending
- 2006-05-02 EP EP19153520.2A patent/EP3520823B1/en active Active
- 2006-05-02 AT AT06759081T patent/ATE525092T1/de not_active IP Right Cessation
- 2006-05-02 BR BRPI0611379-6A patent/BRPI0611379A2/pt not_active Application Discontinuation
- 2006-05-02 EP EP16162716.1A patent/EP3058959B1/en active Active
- 2006-05-02 CN CN201410483749.6A patent/CN104306986A/zh active Pending
- 2006-05-02 CN CNA2006800237754A patent/CN101212988A/zh active Pending
2007
- 2007-11-01 IL IL187078A patent/IL187078A/en not_active IP Right Cessation
- 2007-11-02 US US11/934,325 patent/US10632213B2/en active Active
2013
- 2013-09-27 JP JP2013201138A patent/JP2014037418A/ja active Pending
2015
- 2015-06-03 IL IL239167A patent/IL239167A0/en unknown
- 2015-10-02 JP JP2015197051A patent/JP6338560B2/ja active Active
2020
- 2020-03-03 US US16/808,206 patent/US11957765B2/en active Active

Also Published As

Publication number	Publication date
US10632213B2 (en)	2020-04-28
JP6338560B2 (ja)	2018-06-06
CA2998603A1 (en)	2006-11-09
JP2016041706A (ja)	2016-03-31
AU2006243776A1 (en)	2006-11-09
PL3058959T3 (pl)	2019-07-31
BRPI0611379A2 (pt)	2010-08-31
CA2607173A1 (en)	2006-11-09
JP5829372B2 (ja)	2015-12-09
PL2420256T3 (pl)	2016-12-30
JP2008540445A (ja)	2008-11-20
EP2420256B1 (en)	2016-06-22
IL187078A0 (en)	2008-02-09
US20140356327A9 (en)	2014-12-04
PT1879624E (pt)	2012-02-02
US20200306387A1 (en)	2020-10-01
ES2887076T3 (es)	2021-12-21
PT3520823T (pt)	2021-09-16
EP1879624A1 (en)	2008-01-23
CA2607173C (en)	2018-04-24
CA2998603C (en)	2019-07-23
CN107007842A (zh)	2017-08-04
EP3520823B1 (en)	2021-06-30
EP3058959B1 (en)	2019-01-30
EP2420256A1 (en)	2012-02-22
PT2420256T (pt)	2016-09-13
EP1879624B1 (en)	2011-09-21
EP3058959A1 (en)	2016-08-24
WO2006119458A9 (en)	2007-02-15
IL239167A0 (en)	2015-07-30
PL3520823T3 (pl)	2021-11-22
JP2014037418A (ja)	2014-02-27
PT3058959T (pt)	2019-05-24
IL187078A (en)	2015-06-30
US11957765B2 (en)	2024-04-16
CN101212988A (zh)	2008-07-02
CN107362371A (zh)	2017-11-21
CN104306986A (zh)	2015-01-28
EP1879624A4 (en)	2009-03-25
EP3520823A1 (en)	2019-08-07
WO2006119458A1 (en)	2006-11-09
ATE525092T1 (de)	2011-10-15
US20080292593A1 (en)	2008-11-27

Publication	Publication Date	Title
PT3520823T (pt)	2021-09-16	Terapia genética para distúrbios neurometabólicos
WO2005120581A3 (en)	2006-08-24	Gene therapy for neurometabolic disorders
MX2012005131A (es)	2012-05-29	Enfoques terapeuticos nuevos para tratar la enfermedad de alzheimer.
Kim et al.	2009	Stem cell‐based cell therapy in neurological diseases: a review
Snyder et al.	2004	Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system
PH12020551180A1 (en)	2021-06-07	Methods and compositions for therapeutic protein delivery
HRP20171165T1 (hr)	2017-12-15	Genska terapija za lizosomske bolesti nakupljanja
UA92472C2 (ru)	2010-11-10	Фармацевтическая композиция, которая содержит 4-{4-[3-(4-хлор-3-трифторметилфенил)-уреидо]- 3-фторфенокси}-пиридин-2-карбоновой кислоты метиламид (варианты), способ получения твердой дисперсии указанного соединения и способ лечения с применением указанного соединения (варианты)
MX2021012184A (es)	2022-01-24	Terapias genicas para trastornos lisosomales.
MX2009002816A (es)	2009-05-28	Proteinas de fusion de albumina.
PT1782825E (pt)	2014-11-04	Tratamento de doenças de armazenanto de glicogénio tipo ii
WO2007118245A3 (en)	2008-11-13	Methods and compositions related to adenoassociated virus-phage particles
Kim et al.	2014	Amyotrophic lateral sclerosis-cell based therapy and novel therapeutic development
WO2006083797A3 (en)	2008-10-30	Improving and protecting cell therapy for neurological disorders including parkinson's disease
WO2007132292A3 (en)	2008-06-12	Therapy for alzheimer's disease
WO2002007774A3 (en)	2003-01-16	Methods for therapy of neurodegenerative disease of the brain
WO2006057945A3 (en)	2006-11-09	2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
EP1149917A3 (en)	2001-11-14	Hepatitis B virus vectors for gene therapy
WO2001020025A3 (en)	2001-10-11	Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications
Sousa et al.	2023	Attenuation of ferroptosis as a potential therapeutic target for neuropsychiatric manifestations of post-COVID syndrome
EP1786474A4 (en)	2008-11-19	COMBINED GENE THERAPY FOR THE TREATMENT OF MACROSCOPIC GLIOMES
WO2022035903A3 (en)	2022-09-29	Gene therapies for lysosomal disorders
Kaur et al.	2022	An update on the approaches of avoidance of propagation of chronic kidney disease resulting in reversal or possible need or avoidance of kidney transplantation-a systematic review
WO2005074605A3 (en)	2006-05-26	Recombinant molecular products for expression of heme oxygenase-1, heme oxygenase-2, and/or biliverdin reductase for treatment of neurodegenerative diseases or disorders
WO2006044665A3 (en)	2007-07-05	Neuroprotective spirostenol pharmaceutical compositions